These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 9664134)

  • 1. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
    Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
    J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xenogeneic DNA immunization in melanoma models for minimal residual disease.
    Hawkins WG; Gold JS; Blachere NE; Bowne WB; Hoos A; Lewis JJ; Houghton AN
    J Surg Res; 2002 Feb; 102(2):137-43. PubMed ID: 11796010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
    Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
    Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
    Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
    Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
    Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
    Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigens and cytokine genes in antitumor vaccines: the importance of the temporal delivery sequence in antitumor signals.
    Herrero MJ; Botella R; Dasí F; Algás R; Sánchez M; Aliño SF
    Ann N Y Acad Sci; 2006 Dec; 1091():412-24. PubMed ID: 17341632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
    Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.
    Chatterjee SK; Qin H; Manna S; Tripathi PK
    Anticancer Res; 1999; 19(4B):2869-73. PubMed ID: 10652566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
    Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.